Apr 24, 2025 4:15pm EDT Ensysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds
Apr 23, 2025 4:41pm EDT Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds
Apr 23, 2025 8:00am EDT Ensysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder
Apr 15, 2025 8:00am EDT Ensysce Biosciences Announces Positive Data from Opioid Overdose Protection Study
Mar 31, 2025 8:00am EDT Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Mar 18, 2025 8:00am EDT Ensysce Biosciences Announces PAINWeek 2025 Symposium and Recent Expert Panel Discussion on The State of the Nation in Pain
Mar 10, 2025 4:15pm EDT Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results
Feb 05, 2025 8:00am EST Ensysce Biosciences Reports Continued Positive Progress in Groundbreaking Trial on PF614-MPAR, Comments on Current Landscape for Pain Treatment
Jan 22, 2025 8:00am EST Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR